As integrative and emerging therapies gain momentum, many healthcare providers across Europe and the United States are offering promising—but not yet approved—treatments for conditions such as Parkinson’s Disease, Alzheimer’s, and other neurodegenerative disorders. However, the absence of standardized data systems can make it challenging to consistently track outcomes, safety, and overall effectiveness.
Performance Medical Technologies (PMT) is developing a secure, AI-driven platform designed to support providers in this space—offering practical tools to document care, analyze emerging trends, and build an evidence base that can inform future clinical studies and accelerate responsible innovation.
Across Italy and the EU, more clinicians are exploring non-traditional therapies for neurodegenerative conditions. Yet without a unified system to capture and analyze treatment data, they face key challenges:
As interest in innovative care expands, so does the need for tools that uphold clinical rigor and support research progress.
Italy—especially regions like Friuli Venezia Giulia (FVG)—offers a unique environment to pioneer this system:
PMT’s platform is being piloted with Italian providers to offer a compliant, secure, and user-friendly system for real-world evidence capture—positioning clinics to participate in future clinical trials, regulatory submissions, and international data collaborations.
By helping providers document safety, effectiveness, and treatment variability, PMT’s system does more than just streamline operations—it generates the real-world data needed to support formal clinical validation in both the U.S. and EU.
Whether you’re a physician in Milan offering a therapy for neuroprotection, or a research site in Virginia preparing for a clinical trial, our system gives you the tools to operate ethically, efficiently, and with an eye toward regulatory readiness.
If you’re a provider using non-approved therapies, it’s time to future-proof your practice. PMT’s AI-powered data system turns every patient interaction into clinical insight—and every clinic into a research ally.
Together, we can advance therapies from anecdote to approval—one data point at a time.
